INTRODUCTION: @entity11529 is the most common childhood @entity5 . These @entity5 can cause significant functional and cosmetic problems. While there are many treatment modalities, @entity1169 is increasingly being recognised as the first-line treatment of problematic haemangiomas. This study investigates the use of oral @entity1169 for the treatment of all haemangiomas at a tertiary @entity1 's hospital. METHOD: This is a retrospective study evaluating 15 @entity1 (3 @entity1 and 12 @entity1 ) presenting at a tertiary @entity1 's hospital with @entity11529 during a 24-month period. The protocol consisted of pre-treatment ultrasonic evaluation of the lesion, followed by the commencement of @entity1169 therapy (2  mg/kg orally in two divided doses), with repeat imaging performed at 16-24  weeks in order to document the dimensional changes. Adverse effects of @entity1169 were documented. Intralesional @entity1732 was utilised as a second-line modality of treatment for large or problematic haemangiomas with inadequate regression in size after oral @entity1169 therapy. RESULT: Fifteen (15) @entity1 with a mean age of 7  months (Range: 3-14  months) presented with haemangiomas. Ten @entity1 presented with lesions affecting the head and neck region (67  %). Three @entity1 presented with an @entity1066 , which responded to @entity1169 and simple dressings and all healed completely. The average decrease in size between the ultrasonography procedures was 48.87  %. Only one @entity1 showed no improvement. No side effects were reported. Concomitant @entity1732 treatment was reserved for large problematic haemangiomas and proved successful at speeding up the involution process. CONCLUSION: This study suggests that @entity1169 become the first-line treatment of choice for all haemangiomas. It has proven to be effective and safe for reducing the size of all haemangiomas during the proliferative phase. LEVEL OF EVIDENCE IV: This journal requires that authors assign a level of evidence to each article. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .

Shouldn't XXXX Be Used to Treat All Haemangiomas?

@entity11529 :: ('MESH:D020936', 'Disease') :: ['infantile haemangioma', 'Infantile haemangioma'] @entity1 :: ('9606', 'Species') :: ['children', 'patients', 'patient', 'girls', 'boys'] @entity1169 :: ('MESH:D011433', 'Chemical') :: ['propranolol'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumours', 'tumour'] @entity1066 :: ('MESH:D014456', 'Disease') :: ['ulcerated haemangioma'] @entity1732 :: ('MESH:D001761', 'Chemical') :: ['bleomycin']
@entity1169 :: (MESH:D011433,Chemical) :: ['Propranolol']
